Rhabdomyosarcoma historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
[[Rhabdomyosarcoma]] is considered as the most common [[malignant]] [[soft tissue]] [[tumors]] and the third most common extracranial [[solid tumors]] during childhood. [[Rhabdomyosarcoma]] was firstly described by Weber (German physician) in 1854. In 1946, distinct [[morphology]], [[histology]], and [[classification]] of [[rhabdomyosarcoma]] was understood by Arthur Stout. Stout announced Rhabdomyoblasts as a round, strap, racquet, and spider forms. 


==Historical Perspective==
==Historical Perspective==
Line 12: Line 13:
* Stout announced Rhabdomyoblasts as a round, strap, racquet, and spider forms.<ref name="pmid28256213">{{cite journal| author=El Demellawy D, McGowan-Jordan J, de Nanassy J, Chernetsova E, Nasr A| title=Update on molecular findings in rhabdomyosarcoma. | journal=Pathology | year= 2017 | volume= 49 | issue= 3 | pages= 238-246 | pmid=28256213 | doi=10.1016/j.pathol.2016.12.345 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28256213  }} </ref>
* Stout announced Rhabdomyoblasts as a round, strap, racquet, and spider forms.<ref name="pmid28256213">{{cite journal| author=El Demellawy D, McGowan-Jordan J, de Nanassy J, Chernetsova E, Nasr A| title=Update on molecular findings in rhabdomyosarcoma. | journal=Pathology | year= 2017 | volume= 49 | issue= 3 | pages= 238-246 | pmid=28256213 | doi=10.1016/j.pathol.2016.12.345 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28256213  }} </ref>
* Intergroup Rhabdomyosarcoma Study Group (IRSG) conducted thirty years of investigation about [[rhabdomyosarcoma]].
* Intergroup Rhabdomyosarcoma Study Group (IRSG) conducted thirty years of investigation about [[rhabdomyosarcoma]].
===Landmark Events in the Development of Treatment Strategies===
*Improvement of knowledge and treatment of [[rhabdomyosarcoma]] was mostly came by cooperative group studies because this was not possible for a single institution or regional centers to conduct studies about [[biology]] and treatment of [[rhabdomyosarcoma]] due to variable nature and uncommon occurrence of [[tumors]].<ref name="pmid21357792">{{cite journal| author=Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX et al.| title=Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group. | journal=J Clin Oncol | year= 2011 | volume= 29 | issue= 10 | pages= 1304-11 | pmid=21357792 | doi=10.1200/JCO.2010.29.4611 | pmc=3083998 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21357792  }} </ref>


==References==
==References==
Line 19: Line 23:
{{WS}}
{{WS}}


[[Category:Needs content]]
[[Category:Disease]]
[[Category:Disease]]
  [[Category:Up-To-Date]]
  [[Category:Up-To-Date]]

Latest revision as of 14:37, 13 March 2019

Rhabdomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rhabdomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rhabdomyosarcoma historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rhabdomyosarcoma historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rhabdomyosarcoma historical perspective

CDC on Rhabdomyosarcoma historical perspective

Rhabdomyosarcoma historical perspective in the news

Blogs on Rhabdomyosarcoma historical perspective

Directions to Hospitals Treating Rhabdomyosarcoma

Risk calculators and risk factors for Rhabdomyosarcoma historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]

Overview

Rhabdomyosarcoma is considered as the most common malignant soft tissue tumors and the third most common extracranial solid tumors during childhood. Rhabdomyosarcoma was firstly described by Weber (German physician) in 1854. In 1946, distinct morphology, histology, and classification of rhabdomyosarcoma was understood by Arthur Stout. Stout announced Rhabdomyoblasts as a round, strap, racquet, and spider forms.

Historical Perspective

Discovery

  • Rhabdomyosarcoma is derived from two Greek words, Rhabdo means rod shape and myo means muscle.[1]
  • Rhabdomyosarcoma was firstly described by Weber (German physician) in 1854.
  • In 1946, distinct morphology, histology, and classification of rhabdomyosarcoma was understood by Arthur Stout.[2]
  • Stout announced Rhabdomyoblasts as a round, strap, racquet, and spider forms.[3]
  • Intergroup Rhabdomyosarcoma Study Group (IRSG) conducted thirty years of investigation about rhabdomyosarcoma.

Landmark Events in the Development of Treatment Strategies

  • Improvement of knowledge and treatment of rhabdomyosarcoma was mostly came by cooperative group studies because this was not possible for a single institution or regional centers to conduct studies about biology and treatment of rhabdomyosarcoma due to variable nature and uncommon occurrence of tumors.[4]

References

  1. STOUT AP (1946). "Rhabdomyosarcoma of the skeletal muscles". Ann Surg. 123: 447–72. PMID 21018470.
  2. Stout AP (1946). "Rhabdomyosarcoma of the Skeletal Muscles". Ann Surg. 123 (3): 447–72. PMC 1803493. PMID 17858752.
  3. El Demellawy D, McGowan-Jordan J, de Nanassy J, Chernetsova E, Nasr A (2017). "Update on molecular findings in rhabdomyosarcoma". Pathology. 49 (3): 238–246. doi:10.1016/j.pathol.2016.12.345. PMID 28256213.
  4. Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX; et al. (2011). "Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group". J Clin Oncol. 29 (10): 1304–11. doi:10.1200/JCO.2010.29.4611. PMC 3083998. PMID 21357792.

Template:WH Template:WS